Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase

被引:28
|
作者
van der Wildt, Berend [1 ,2 ,3 ,4 ]
Wilhelmus, Micha M. M. [3 ,4 ]
Bijkerk, Jonne [1 ,2 ]
Haveman, Lizeth Y. F. [1 ,2 ]
Kooijman, Esther J. M. [1 ,2 ]
Schuit, Robert C. [1 ,2 ]
Bol, John G. J. M. [3 ,4 ]
Jongenelen, Cornelis A. M. [3 ,4 ]
Lammertsma, Adriaan A. [1 ,2 ]
Drukarch, Benjamin [3 ,4 ]
Windhorst, Albert D. [1 ,2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Radiol, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Nucl Med, NL-1081 HV Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Anat, NL-1081 HV Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Neurosci, NL-1081 HV Amsterdam, Netherlands
关键词
Tissue transglutaminase; TG2; Carbon-11; Carbonylation; C-11]acryl amides; MDA-MB-231; MONOXIDE; INHIBITORS; PRESSURE; AMINES; TARGET;
D O I
10.1016/j.nucmedbio.2016.01.003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Tissue transglutaminase (TG2) is a ubiquitously expressed enzyme capable of forming metabolically and mechanically stable crosslinks between the gamma-carboxamide of a glutamine acyl-acceptor substrate and the epsilon-amino functionality of a lysine acyl-donor substrate resulting in protein oligomers. High TG2 crosslinking activity has been implicated in the pathogenesis of various diseases including celiac disease, cancer and fibrotic and neurodegenerative diseases. Development of a PET tracer specific for active TG2 provides a novel tool to further investigate TG2 biology in vivo in disease states. Recently, potent irreversible active site TG2 inhibitors carrying an acrylamide warhead were synthesized and pharmacologically characterized. Methods: Three of these inhibitors, compound I, 2 and 3, were successfully radiolabeled with carbon-11 on the acrylamide carbonyl position using a palladium mediated [C-11]CO aminocarbonylation reaction. Ex vivo biodistribution and plasma stability were evaluated in healthy Wistar rats. Autoradiography was performed on MDA-MB-231 tumor sections. Results: [C-11]1.-2 and -3 were obtained in decay corrected radiochemical yields of 38-55%. Biodistribution showed low uptake in peripheral tissues, with the exception of liver and kidney. Low brain uptake of <0.05% ID/g was observed. Blood plasma analysis demonstrated that [C-11] and [C-11]2 were rapidly metabolized, whereas [C-11]3 was metabolized at a more moderate rate (63.2 +/- 6.8 and 28.7 +/- 10.8% intact tracer after 15 and 45 min, respectively). Autoradiography with [C-11]3 on MDA-MB-231 tumor sections showed selective and specific binding of the radiotracer to the active state of TG2. Conclusions: Taken together, these results identify [C-11]3 as the most promising of the three compounds tested for development as PET radiotracer for the in vivo investigation of TG2 activity. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:232 / 242
页数:11
相关论文
共 50 条
  • [1] Evaluation of novel carbon-11 labeled tissue transglutaminase inhibitors
    van der Wildt, Berend
    Bijkerk, Jonne
    Kooijman, Esther J.
    Schuit, Robert
    Drukarch, Benjamin
    Lammertsma, Adriaan A.
    Windhorst, Albert D.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2015, 58 : S38 - S38
  • [2] Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase
    van der Wildt, Berend
    Wilhelmus, Micha M. M.
    Kooijman, Esther J. M.
    Jongenelen, Cornelis A. M.
    Schuit, Robert C.
    Buechold, Christian
    Pasternack, Ralf
    Lammertsma, Adriaan A.
    Drukarch, Benjamin
    Windhorst, Albert D.
    NUCLEAR MEDICINE AND BIOLOGY, 2017, 44 : 90 - 104
  • [3] Imaging the distribution of Carbon-11 labeled rifampicin, isoniazid and pyrazinamide in baboons using PET
    Liu, Li
    Xu, Youwen
    Shea, Colleen
    Fowler, Joanna
    Hooker, Jacob
    Tonge, Peter
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [4] Imaging the Distribution of Carbon-11 Labeled Rifampicin, Isoniazid and Pyrazinamide in Baboons using PET
    Liu, Li
    Hooker, Jacob M.
    Fowler, Joanna S.
    Tonge, Peter J.
    FASEB JOURNAL, 2010, 24
  • [5] Carbon-11 labeled methotrexate derivatives for tumor imaging
    Papachristou, Maria
    Zhong, Ziyun
    Ouchi, Erika
    Datseris, Ioannis
    Scott, Peter
    Shao, Xia
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S461 - S462
  • [6] Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation
    Gao, Mingzhang
    Wang, Min
    Miller, Kathy D.
    Hutchins, Gary D.
    Zheng, Qi-Huang
    APPLIED RADIATION AND ISOTOPES, 2009, 67 (11) : 2019 - 2024
  • [7] Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter
    Ben-Daniel, R.
    Deuther-Conrad, W.
    Scheunemann, M.
    Steinbach, J.
    Brust, P.
    Mishani, E.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (12) : 6364 - 6370
  • [8] SYNTHESIS OF CARBON-11 LABELED CAMPTOTHECIN DERIVATIVES AS NOVEL PET TRACERS FOR IMAGING OF TOPOISOMERASE IN CANCERS
    Gao, M.
    Miller, K. D.
    Sledge, G. W.
    Zheng, O. -H.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2005, 48 : S176 - S176
  • [9] Radiosynthesis of Carbon-11 Labeled Puromycin as a Potential PET Candidate for Imaging Protein Synthesis in Vivo
    Sephton, Selena Milicevic
    Aigbirhio, Franklin I.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (06): : 647 - 651
  • [10] Synthesis of carbon-11 labeled triphenylacetamides as novel potential PET melanoma cancer imaging agents
    Gao, Mingzhang
    Kong, Deyuan
    Clearfield, Abraham
    Miller, Kathy D.
    Sledge, George W.
    Zheng, Qi-Huang
    SYNTHESIS-STUTTGART, 2006, (14): : 2301 - 2304